^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + benmelstobart (APL-502) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase I/II Study of TQ-B2450 plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies:Phase II Results Updates
Published date:
08/08/2023
Excerpt:
Among all, 14 achieved confirmed PR, 36 achieved SD, the ORR was 25.5% (14/55) and the DCR was 90.9% (50/55). The median PFS was 9.0 months (95% CI 5.2 to 12.9), 6-month PFS rate was 68.0% and 9-month PFS rate was 51.6%. Overall, TQ-B2450 and anlotinib was well tolerated...The chemo-free combination of TQ-B2450 and anlotinib has shown incredible anti-tumor efficacy and well tolerance in the treatment of EGFR+ advanced NSCLC who failed to prior EGFR TKI therapies.
Source:
Title:
150P - A phase I study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR+ advanced NSCLC patients failed to prior EGFR TKI therapies
Published date:
03/17/2021
Excerpt:
Pts with EGFR+ advanced NSCLC who failed to prior EGFR TKI therapies were eligible….Among 9 evaluable pts, DCR was 77.8% (7/9) and the other 2 pts had disease progression, the median PFS was 9.1 months (95% CI [4.2. 9.3])….TQ-B2450 plus anlotinib was well tolerated with evidence of clinical activity.
